Conduit Company Profile: CDT Business, Executives & Facts

Key StatisticsCurrency:USD

EPS(TTM)

-0.20

P/E(TTM)

-0.45

BVPS

-0.095

P/B

-0.74

Revenue(2024 Q3)

--

YoY

--

Net Income(2024 Q3)

-6.46M

YoY

-346.13%

Gross Margin(TTM)

--

Net Margin(TTM)

--

ROE(TTM)

--

Debt ratio

404.64%

Dividend Yield(TTM)

--

Payout Ratio

--

Profile

Conduit Pharmaceuticals Inc.

 A clinical-stage specialty biopharmaceutical company serving unmet medical needs in autoimmune diseases and idiopathic male infertility. 

Conduit Pharmaceuticals Inc., is incorporated in Delaware. Conduit has developed a unique business model that enables it to act as a conduit for bringing clinical assets from pharmaceutical companies and developing new therapies for patients. The Company's new approach addresses unmet medical needs and extends intellectual property to the Company's existing assets by commercializing the Company's products through cutting-edge solid-state technology and corporate and life science companies.

Related Sections

Biotechnology+0.78%

Revenue BreakdownCurrency:USD

No Data

Major shareholders

Murphy Canyon Acquisition Sponsor, LLC

DividendsCurrency:USD

No Data

Net Income Attributable to Parent

Total Cash Dividends

Payout Ratio

Institutional Holdings

Totally

42

institutions reported their ownerships on

CDT

Institutional Holding Ratio

Price

Insider Transactions

Net increase

Net decrease

Price

Stock split and consolidation

Executive Profile

Feedback

Disclaimer: All data and information presented above are from third-party data sources. They are for reference only and do not constitute any investment advice.

Market Data Risk Disclosure|Privacy Policy